Abstract

Obesity is associated with dyslipidemia and lipid deposition into liver tissue. Circulating endothelin-1 (ET-1) is elevated in patients with obesity, and our lab has demonstrated that ET-1 is increased in liver of mice fed high fat (HFD). Interestingly, treatment with atrasentan attenuates reduces circulating triglycerides and free fatty acids and reduces lipid deposition into liver of mice fed HFD for 10 weeks; however, the mechanisms are not known. Perilipin 2 (Plin2) is a protein expressed in adipocytes and hepatocytes that is integral to lipid droplet formation by forming a coating around the droplet. We hypothesized that ET-1 receptor blockade reduces liver lipid deposition in obese mice by reducing Plin2 expression. To test this hypothesis, mice were fed normal (NMD) or HFD for 10 weeks and treated with the ET-1 receptor A (ETA) antagonist atrasentan for weeks 9-10. ET-1 receptor expression was significantly increased in HFD fed mice compared to NMD. As previously demonstrated, HFD fed mice had significantly higher liver triglyceride content compared to NMD controls, and this was attenuated in mice treated with atrasentan (ATR). As expected, Plin2 expression in liver tissue was significantly elevated in HFD mice compared to NMD (91.7±17.4 vs. 60.8±14.4 copies/pg RNA), an affect that was abolished in mice treated with atrasentan (NMD, 60.8±14.4; HFD, 91.7±17.4; NMD + ATR, 70.2±10.8; HFD + ATR, 26.3±5.8 copies/10pg RNA). These data suggest that ET-1 promotes lipid accumulation in liver of obese mice by reducing Plin2 expression. Funding: R01 DK124437, P30GM149404, and T32HL105324. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.